# Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

> **NCT01263951** · PHASE2 · UNKNOWN · sponsor: **Thomas Jefferson University** · enrollment: 35 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01263951
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2021-02-01
- **Final completion:** 2022-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263951, "Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01263951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*